[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100308555":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":36,"collaborators":38,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"BRCA1\u002F2 variant carriers",null,"Japanese women who carry BRCA 1\u002F2 variants.",[13],{"name":14,"affiliation":15,"role":16},"Akira Hirasawa, M.D., Ph.D.","Okayama University","STUDY_CHAIR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+81-86-235-7436","hir-aki45@umin.org",[23],{"facility":15,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Okayama","Japan","JP",{"type":29,"coordinates":30},"Point",[31,32],133.93333,34.65,{"lat":32,"lon":31},[35],{"name":14,"role":19,"phone":10,"phoneExt":10,"email":10},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[39,40],{"name":15,"class":6},{"name":41,"class":6},"Japanese Gynecologic Oncology Group","100308555","prospective-cohort-study-of-germline-variant-carriers-with-brca1-or-brca2-100308555",false,"NCT03296826","Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2","Inclusion Criteria:\n\n1. Women carrying BRCA1\u002F2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).\n2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.\n3. Women who provide consent should be 20 years of age or older.\n4. Women who provide written consent.\n\nExclusion Criteria:\n\n1. Women without ovarian or fallopian tube cancer at the time of informed consent.\n2. Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.\n3. Other individuals considered inappropriate for involvement in this study by the investigator.","FEMALE","20 Years",{"count":51,"type":52},600,"ESTIMATED","OBSERVATIONAL","To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1\u002F2 variants.",[56,57,58,59],"BRCA1 and\u002For BRCA2 Variant Carriers","Ovarian Carcinoma","Fallopian Tube Carcinoma","Peritoneal Carcinoma","2026-01-30",{"date":62,"type":63},"2026-02-03","ACTUAL",{"date":65,"type":63},"2017-11-08",{"date":67,"type":52},"2032-03-31",{"name":5,"class":6},1]